Founded in 2018 by Aaron Hannon, Dr. Barbara Oliveira and Professor Martin O’Halloran, Luminate builds an ecosystem that lets cancer patients receive treatment at home rather than in hospital settings. Its first two devices, Lilac and Lily, are designed to mitigate common chemotherapy side effects—peripheral neuropathy and hair loss—and are currently in multi-center clinical trials across the US and Europe, with commercial launch targeted for 2027. The company plans to open access to home cancer care at 40 partner oncology clinics and introduce a patient-led home infusion technology by mid-2026. Clinical data from its neuropathy prevention study are expected in mid-2026, which will inform regulatory and market rollout. Luminate operates from Galway with additional offices in Chicago, San Antonio and Omaha. Including the latest raise, the startup has secured $50 million in funding to date, supporting product development, clinical validation and commercial expansion.

Total raised

$41M

Funding rounds

4

Latest round

Series A

Latest activity

Jan 2026